U
14.20
0.42 (3.05%)
| Previous Close | 13.78 |
| Open | 14.00 |
| Volume | 1,017,054 |
| Avg. Volume (3M) | 1,114,973 |
| Market Cap | 767,891,968 |
| Price / Earnings (Forward) | 27.93 |
| Price / Sales | 16.06 |
| Price / Book | 2.83 |
| 52 Weeks Range | |
| Earnings Date | 27 Feb 2025 |
| Operating Margin (TTM) | -796.27% |
| Diluted EPS (TTM) | -4.92 |
| Quarterly Revenue Growth (YOY) | -21.90% |
| Total Debt/Equity (MRQ) | 889.83% |
| Current Ratio (MRQ) | 9.74 |
| Operating Cash Flow (TTM) | -182.73 M |
| Levered Free Cash Flow (TTM) | -139.79 M |
| Return on Assets (TTM) | -16.39% |
| Return on Equity (TTM) | -238.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | uniQure N.V. | Bullish | Bullish |
AIStockmoo Score
0.4
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.38 |
|
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.59% |
| % Held by Institutions | 77.61% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (HC Wainwright & Co., 392.96%) | Buy |
| Median | 38.00 (167.61%) | |
| Low | 30.00 (Wells Fargo, 111.27%) | Hold |
| Average | 46.00 (223.94%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 13.81 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 06 May 2025 | 38.00 (167.61%) | Buy | 15.00 |
| 01 Apr 2025 | 38.00 (167.61%) | Buy | 9.91 | |
| HC Wainwright & Co. | 21 Apr 2025 | 70.00 (392.96%) | Buy | 13.29 |
| 04 Mar 2025 | 70.00 (392.96%) | Buy | 11.33 | |
| Wells Fargo | 28 Feb 2025 | 30.00 (111.27%) | Hold | 13.15 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 May 2025 | Announcement | uniQure to Announce First Quarter 2025 Financial Results |
| 17 Apr 2025 | Announcement | uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease |
| 27 Feb 2025 | Announcement | uniQure Announces 2024 Financial Results and Highlights Recent Company Progress |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |